首页> 美国卫生研究院文献>Oncology Reports >Gene expression and prognosis of insulin-like growth factor-binding protein family members in non-small cell lung cancer
【2h】

Gene expression and prognosis of insulin-like growth factor-binding protein family members in non-small cell lung cancer

机译:胰岛素样生长因子结合蛋白家族成员在非小细胞肺癌中的基因表达及预后

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lung cancer is the leading cause of cancer mortality worldwide. Approximately 85% of all lung cancer cases are classified as non-small cell lung cancer (NSCLC). Currently, there is no standard method to predict the survival of patients with NSCLC. Insulin-like growth factor-binding proteins (IGFBPs) function as modulators of IGF signaling and are attracting increasing attention for their role in NSCLC. However, the prognostic values of individual IGFBPs in NSCLC, particularly at the mRNA level, remain unknown. In the present study, the distinct expression patterns and prognostic values of IGFBP family members in patients with NSCLC through bioinformatics analysis were reported using a series of databases, including Gene Expression Profiling Interactive Analysis, Kaplan-Meier Plotter, cBioPortal, GeneMANIA, and the Database for Annotation, Visualization and Integrated Discovery. In patients with NSCLC, IGFBP2 and IGFBP3 were significantly upregulated, while IGFBP6 was downregulated. High IGFBP1/2/4 expression was correlated with poor overall survival (OS) in all NSCLC types, especially adenocarcinoma; however, high IGFBP2/5 expression was significantly correlated with favorable OS only in patients with squamous cell carcinoma. In addition, aberrant IGFBP1/2/3/4/5 mRNA levels were associated with the prognosis of subsets of NSCLC with different clinicopathological features. These results indicated that various IGFBPs can serve as useful prognostic biomarkers and as potential targets for NSCLC therapies.
机译:肺癌是全球癌症死亡的主要原因。所有肺癌病例中约有85%被归类为非小细胞肺癌(NSCLC)。当前,尚无标准方法来预测NSCLC患者的生存。胰岛素样生长因子结合蛋白(IGFBPs)作为IGF信号的调节剂,并因其在NSCLC中的作用而受到越来越多的关注。但是,单个IGFBPs在NSCLC中的预后价值,尤其是在mRNA水平,尚不清楚。在本研究中,使用一系列数据库,包括基因表达谱分析,Kaplan-Meier绘图仪,cBioPortal,GeneMANIA和数据库,通过生物信息学分析报告了NSCLC患者IGFBP家族成员在生物信息学分析中的独特表达模式和预后价值。用于注释,可视化和集成发现。在NSCLC患者中,IGFBP2和IGFBP3显着上调,而IGFBP6下调。在所有NSCLC类型,特别是腺癌中,IGFBP1 / 2/4的高表达与总生存期(OS)差有关。然而,仅在鳞状细胞癌患者中,IGFBP2 / 5的高表达与良好的OS显着相关。此外,异常IGFBP1 / 2/3/4/5 mRNA水平与具有不同临床病理特征的NSCLC亚群的预后相关。这些结果表明,各种IGFBP可作为有用的预后生物标志物,并可作为NSCLC治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号